Lesetipps: Aktuell relevante Publikationen für die Dermatologie
Viel Spaß Ihnen bei unserer Lektüreauswahl der informativen Publikationen in den dermatologischen Fachmedien. Die Auswahl umfasst Links zu den renommiertesten internationalen Fachmagazinen.
Hier finden Sie unter anderem interessante Links zu Publikationen rund um den Wirkstoff Tildrakizumab.
Unsere Auswahl relevanter Publikationen zu Tildrakizumab
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, et al.
Br J Dermatol. 2018;179; 615-622.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al.
Br J Dermatol. 2020;182; 605-617.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al.
Br J Dermatol. 2021;185; 323-334.
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.
Thaci D, Jullien D, Egeberg A, Carrascosa JM, Wu JJ, Pau-Charles I, et al.
J Eur Acad Dermatol Venereol. 2021.
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, et al.
J Eur Acad Dermatol Venereol. 2021;35; 919-927.
Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.
Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B.
J Eur Acad Dermatol Venereol. 2022.
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L, et al.
J Clin Med. 2022;11.
Improvement During Tildrakizumab Therapy: A Real-Life Experience.
Brunasso A.
Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience. J Drugs Dermatol. 2022;21(8):914-916. doi:10.36849/JDD.6828.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Mastorino L, Cariti C, Susca S, Sciamarrelli N, Borriello S, Ortoncelli M, et al.
Dermatol Ther. 2022; e15818.
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al.
Ann Rheum Dis. 2021.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi C, et al.
J Eur Acad Dermatol Venereol. 2022.
